Justin Fulcher stepped back from RingMD in January 2025 after nearly a decade at the helm. By then, the telehealth platform the technology founder had built was operating across more than fifty countries, held 1.5 million patient records, and maintained an active network of 10,000 healthcare providers. Its clients included governments, hospital systems, insurers, and pharmaceutical firms, among them India's Digital India programme and the US Indian Health Service, where it served approximately 2.6 million American-Indian and Alaska Native individuals across 37 states. The platform earned FedRAMP authorization and achieved FISMA and HIPAA compliance. Forbes named Justin Fulcher to its 30 Under 30 Asia list in 2017.
None of that happened by accident, and none of it happened overnight. RingMD scaled through an intensely regulated, high-stakes industry by making a series of deliberate decisions about where to build, who to build for, and how to earn institutional trust across jurisdictions.
What follows is the playbook behind that growth: the principles that guided how Justin Fulcher took a solo prototype in Southeast Asia and turned it into a platform that governments and health systems across three continents came to rely on.
Most founders plan their way into international expansion. Justin Fulcher built his way into it.
RingMD began as an unnamed prototype: a working build with no pitch deck, no brand, and no formal company behind it. "For a number of months, it was essentially a hobby project," the technology founder has said. Investors approached him, not the other way around, and their interest formalised something that was already functioning.
The advantage of that sequence is easy to overlook. By the time RingMD had a name and a structure, the core product already existed as a working build. Fulcher wasn't raising capital around a slide deck or a market thesis. He was showing investors something he had already made. That meant the company, when it did formalize, was built around a functioning prototype rather than a set of assumptions.
For a technology founder scaling into unfamiliar international markets, starting with something real rather than something theoretical is a meaningful head start.
Justin Fulcher incorporated RingMD in Singapore. English-speaking, business-friendly, and geographically central to the markets where demand for affordable healthcare was most acute, it offered regulatory ease and a commercial environment designed to reduce friction for exactly the kind of company the technology founder was standing up.
It also put him close to the markets that mattered most. India, Indonesia, and the broader Southeast Asian region were complex, varied, and difficult to understand from a distance. Being based in Singapore meant Justin Fulcher could move between those markets quickly and build relationships with the governments, hospitals, and healthcare providers who would eventually become RingMD's core clients. For a company scaling internationally in a regulated industry, choosing a base that sits close to your hardest markets, not your most comfortable ones, is a smart, impactful decision..
Institutional resistance to change often plays a bigger part in damaging scaling and adoption than technical challenges. Institutional drag, not infrastructure, is what stalls most companies trying to operate across regulated environments.
"Telehealth didn't become real because the technology finally arrived," Justin Fulcher has said. "The technology arrived many times. Telehealth became real when systems started treating distance as an ordinary condition rather than a special exception."
Consumer demand was never the issue. In markets where a video consultation with a qualified doctor was the alternative to no healthcare at all, uptake was immediate. The resistance came from institutions: clinicians who viewed remote care with professional unease, regulatory bodies operating on outdated processes, and healthcare systems built around physical proximity as an organizing assumption.
The technology founder's approach to that resistance was consistent across every market RingMD entered. "This is not a replacement for in-person," he told skeptical practitioners. "This is an augmentation to what you're currently doing."
The framing was deliberate: position telehealth as something that expanded a doctor's reach without diminishing their authority. It was an argument that had to be made and won repeatedly, across different countries, regulatory environments, and professional cultures, because institutional trust doesn't transfer from one jurisdiction to the next. You earn it each time or you don't scale.
"In healthcare, the systems that last will always outcompete the ideas that merely impress," Justin Fulcher has said. For any technology founder scaling through regulated environments, that distinction is the difference between a company that grows and one that stalls.
RingMD was engineered from the outset for connectivity in low-bandwidth environments and was designed to function in settings where reliable internet access could not be assumed.
The strategic logic behind that choice becomes clear in hindsight. The Digital India partnership, through which RingMD built a healthcare access gateway reaching 883 million rural residents, required the platform to perform under the most constrained conditions imaginable.
"I saw that trend and also a variety of big needs, such as the need for basic healthcare access," Justin Fulcher said of his early observations in Southeast Asia, "and I thought — why can't we fuse the two and actually build a platform that brings healthcare, through a smartphone, to a rural environment?"
By designing for those environments first, the technology founder ensured the platform was overqualified for less demanding ones. When RingMD later earned FedRAMP authorisation and deployed across US federal health systems, including the Indian Health Service contract serving 2.6 million individuals across 37 states, the architecture had already been proven under harder conditions than any American clinic would present. A product built to work where nothing else does tends to work everywhere else by default.
Scaling across 50 countries in healthcare means operating across multiple jurisdictions with what Justin Fulcher has described as "competing incentives and timelines." There is no shortcut through that complexity, and no single regulatory approval that unlocks every door.
The technology founder built data governance and compliance into the platform's core from the outset. Not as a response to a single client or contract, but as a prerequisite for operating across regulated environments simultaneously. Every interaction on the platform was digitized and stored securely, with data feeding algorithms designed to support clinical decision-making. The compliance infrastructure that followed (FedRAMP Moderate, FISMA, HIPAA) was a natural extension of a company that had been navigating institutional drag across borders from the beginning.
"Building in healthcare requires operating inside real constraints: policy, privacy, clinical standards, and operational complexity, while still delivering outcomes that matter," Fulcher has said. The insight for any founder scaling internationally in a regulated space is that trust is not a phase of growth you complete and move past. It is the growth. Every new jurisdiction, every new institutional client, requires you to earn it again, and the companies that build compliance and data governance into their operating model from day one are the ones positioned to do that at scale.
In 2018, Justin Fulcher sold a majority stake in RingMD and spent approximately a year managing the transition, which included relocating the company's headquarters from Singapore to Boston. The platform relaunched in the US in 2019 with a sharpened focus on government and institutional clients: a pivot from the broad consumer-facing marketplace of the Singapore era to a turnkey, compliance-first telehealth platform built for regulated environments.
"Selling a company can be one of the best things for a business, or it can be a very negative thing, depending on alignment of values," the technology founder has said. "What selling a company ultimately comes down to is a shared vision." He framed the decision not as an exit but as a scaling move, bringing in partners and capital positioned to take the platform further than its existing structure allowed. "This is a continuation of the vision rather than a departure from it," he said at the time.
The instinct for most founders is to hold on. Fulcher's experience suggests that recognizing when a company needs different capital, different leadership, or a different geographic base to reach its next stage, and acting on that recognition, is one of the most important scaling decisions a founder can make. RingMD's trajectory after the sale, including the IHS contract and FedRAMP authorisation, suggests the decision was the right one.
Justin Fulcher's career since RingMD has moved through workforce development, government modernization, defense technology, and public service, from co-founding the Palmetto Initiative in South Carolina to serving as senior advisor to Defense Secretary Pete Hegseth at the Defense Department. The contexts change, but the operating principles don't.
"Durability is not accidental," the technology founder has written. "It is engineered."
The playbook that took RingMD across fifty countries — build before you brand, solve the institutional problem, design for the hardest environment, earn trust jurisdiction by jurisdiction, and know when to hand it off — isn't a healthcare playbook. It's a framework for building companies within complexity. And for a technology founder who has been building since the age of seven, that work is still underway.
"Over time, I've become less interested in celebrating outcomes," Justin Fulcher has said, "and more interested in studying what endures."